MDL | MFCD09266779 |
---|---|
Molecular Weight | 255.35 |
Molecular Formula | C17H21NO |
SMILES | CC(C=C(C)C=C1C)=C1C2=NOC3C2C4CC3CC4 |
EC50: 1.8±0.13 μM (TRPML3), >29.9 μM (TRPML1) [1]
The conductance of TRPML3 channels is estimate, when activated with 10 µM SN-2 is approximately 10 pS at −80 mV. TRPML3-expressing HEK293 cells are perfused with a series starting with compound alone (in SBS), with compound in ELS, and finally with ELS alone. Two representative compounds, SF-24 and SN-2, are tested. SF-24 is one of the least effective compounds, and SN-2 is one of the most active ones. SN-2 has a similar synergistic effect, also reaching up-to 10-fold enhancement of the combined response when compared with the individual responses, reaching average current densities of up to 3 nA/pF at −80 mV. Dominant negative TRPML3(D458K) is highly effective in eliminating SN-2-induced activity in epidermal melanocytes, suggesting that SN-2 activates a channel that is not responsive in presence of TRPML3(D458K). Such a dominant negative action might be attributed to potential heteromerization of TRPML3(D458K) with an SN-2-responsive channel [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
NCT Number | Sponsor | Condition | Start Date | Phase |
---|---|---|---|---|
NCT05484388 | Essity Hygiene and Health AB|Smerud Medical Research Germany Ltd |
Urinary Incontinence
|
October 3, 2022 | Not Applicable |
Solid
Room temperature in continental US; may vary elsewhere.
Powder | -20°C | 3 years |
---|---|---|
4°C | 2 years | |
In solvent | -80°C | 6 months |
-20°C | 1 month |
DMSO : 100 mg/mL ( 391.62 mM ; Need ultrasonic)
Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
---|
1 mM | 3.9162 mL | 19.5810 mL | 39.1619 mL |
5 mM | 0.7832 mL | 3.9162 mL | 7.8324 mL |
10 mM | 0.3916 mL | 1.9581 mL | 3.9162 mL |
Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (9.79 mM); Clear solution